RESUMO
ABSTRACT: Intake of 131I by nuclear medicine technologists and physician Authorized Users was evaluated using bioassay data from administration of 131I sodium iodide in capsular form during a 5-year period. Maximum estimated annual intake of 131I sodium iodide, based on bioassay measurements performed at 24 hours post administration, ranged from 10.9 to 35.6 kBq for all staff. Intake by Authorized Users was higher than that by nuclear medicine technologists due to state requirement for Authorized Users to physically administer therapeutic dosages of radiopharmaceuticals. All intake values were less than 10% of the 131I thyroid ALI of 50 microcurie3 (1,850 kBq), indicating that monitoring may be discontinued for staff participating in routine administration of 131I capsules in which volatilization is not suspected. Elimination of bioassay performance has permitted more flexibility in patient scheduling and improved workflow and efficiency.
Assuntos
Radioisótopos do Iodo , Iodeto de Sódio , Humanos , Radioisótopos do Iodo/uso terapêutico , Compostos Radiofarmacêuticos/uso terapêutico , Iodeto de Sódio/uso terapêutico , Glândula TireoideRESUMO
By simple combination of water and sodium iodide (NaI) with chlorotrimethylsilane (TMSCl), promotion of a Vorbrüggen glycosylation en route to essential HIV drugs emtricitabine (FTC) and lamivudine (3TC) is achieved. TMSCl-NaI in wet solvent (0.1 M water) activates a 1,3-oxathiolanyl acetate donor for N-glycosylation of silylated cytosine derivatives, leading to cis-oxathiolane products with up to 95% yield and >20:1 dr. This telescoped sequence is followed by recrystallization and borohydride reduction, resulting in rapid synthesis of (±)-FTC/3TC from a tartrate diester.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , HIV-1 , Fármacos Anti-HIV/farmacologia , Desoxicitidina/uso terapêutico , Emtricitabina/uso terapêutico , Glicosilação , Infecções por HIV/tratamento farmacológico , Humanos , Lamivudina/uso terapêutico , Iodeto de Sódio/uso terapêutico , Compostos de Trimetilsilil , ÁguaRESUMO
Introducción: La aplicación de actividades fijas en el tratamiento del hipertiroidismo con I131 (yoduro de sodio, conocido también como radioyodo), es el método más usado en nuestro país, a pesar de la individualidad morfo-funcional que caracteriza esta afección. Sin embargo, no existe aún, un consenso internacional sobre la dosis más conveniente para cada caso, y por ende, los resultados no siempre son los deseados. Objetivo: Evaluar la aplicabilidad de varios métodos de cálculo de dosis paciente-específica para el tratamiento de hipertiroidismo con yoduro de sodio. Métodos: Se realizó un análisis de los resultados de varios métodos de cálculo de dosis recomendados internacionalmente a partir de la actividad fija prescrita en 10 pacientes, con el empleo de tecnologías y herramientas ya desarrolladas y disponibles en el país. Se evaluó la variabilidad inter-especialista y su impacto en la dosis planificada para el tratamiento. Resultados: El uso de la información incompleta de la biodistribución y farmacocinética del paciente produjo diferencias entre -42 por ciento y 37 por ciento de las dosis para el mismo paciente. El resultado de la comparación del método de cálculo recomendado por la Sociedad Europea de Medicina Nuclear, manejando la masa por gammagrafía-2D / 3D y por ultrasonido, arrojó diferencias no significativas entre sí. La variabilidad inter-especialista de las actividades prescrita mostró diferencias significativas, que arrojan sobre el mismo paciente, discrepancias entre 44Gy y 243Gy de las dosis terapéuticas a recibir, situación que puede comprometer el éxito del tratamiento y producir efectos secundarios no deseados. Conclusiones: Las técnicas dosimétricas paciente-específicas se pueden implementar satisfactoriamente en nuestro país. Las diferencias numéricas encontradas, especialmente la variabilidad inter-especialista, demuestran la no estandarización terapéutica, lo que apoya el uso de la farmacocinética paciente-específica pre terapéutica y la masa por gammagrafía-3D para planificar el tratamiento siempre que sean posible(AU)
Introduction: Despite of its typical morpho-functional individuality, fixed activities remain as the most used method in Cuba for hyperthyroidism treatment with I (sodium iodide, also known as radioiodine). However, there is not yet an international consensus on the most convenient doses for each case, so, the results are not always the desired ones. Objective: To evaluate the applicability of various patient-specific dose calculation methods for the treatment of hyperthyroidism with sodium iodide. Methods: It was carried out an analysis in 10 patients of the results of some methods for dose calculation from the prescribed fixed activity recommended internationally, with the use of technologies and tools already developed and available in the country. The inter-specialist variability and its impact in the planned dose for the treatment were assessed. Results: The use of uncompleted biodistribution and pharmacokinetics information of the patient showed differences between -42 percent and 37 percent in the doses for the same patient. The outcome of the comparison of the calculation method recommended by the European Society of Nuclear Medicine managing the mass by 3D/2D gammagraphy and ultrasound, presented no significant discrepancies among them. The inter-specialist variability of prescribed activity was statistically significant, and it can produce in the same patient differences between 44Gy and 243Gy of the therapeutic doses, which could affect the treatment success and lead to unnecessary side effects. Conclusions: The patient´s personalized calculation methods can be satisfactorily applied in Cuba. The numeric differences found, especially inter-specialist variability, show the lack of therapeutic standardization, which supports the use of pre-therapeutic patient-specific pharmacokinetics and the mass by 3D-gammagraphy to plan the treatment when possible(AU)
Assuntos
Humanos , Masculino , Feminino , Adulto , Iodeto de Sódio/uso terapêutico , Farmacocinética , Hipotireoidismo/terapia , Medicina Nuclear/métodos , Padrões de ReferênciaRESUMO
PURPOSE: To analyse the activity uptakes, effective half-lives and time-integrated activities, of relevance for remnant dosimetry, for patients treated for papillary thyroid cancer (PTC) with a different amount of activity of 131I-NaI. METHODS: Fifty patients were included. Of those, 18 patients had low-risk PTC and were treated with 1.11â¯GBq of 131I-NaI (Group 1), and 32 patients had high-risk PTC and were treated with 3.7â¯GBq (Group 2). Radioiodine was administered after total thyroidectomy and rhTSH stimulation. Two SPECT/CT scans were performed for each patient to determine the remnant activities and effective half-lives. RESULTS: Significantly higher values (pâ¯<â¯0.05) were obtained for Group 1 for the remnant activity at 7 d (medians 1.4â¯MBq vs 0.27â¯MBq), the remnant activity per administered activity at 2 d (0.35% vs 0.09%) and at 7 d (0.13% vs 0.007%), and the effective half-life (93â¯h vs 40â¯h). Likewise, the time-integrated activity coefficient was significantly higher for Group 1. The time-integrated activity did not differ significantly between the two groups (pâ¯>â¯0.05). CONCLUSIONS: We found a significant difference in the remnant activity per administered activity, the rate of washout from thyroid remnants, and the time-integrated activity coefficient between low-risk PTC patients treated with 1.11â¯GBq and high-risk PTC patients treated with 3.7â¯GBq. On the contrary, there was no such difference in the time-integrated activity. If remnant masses were also not statistically different (reasonable assumption for this monocentric study) no difference in time-integrated activity would imply no difference in remnant absorbed dose, of relevance for treatment efficacy and the risks of stochastic effects.
Assuntos
Radioisótopos do Iodo/uso terapêutico , Iodeto de Sódio/metabolismo , Iodeto de Sódio/uso terapêutico , Câncer Papilífero da Tireoide/metabolismo , Câncer Papilífero da Tireoide/radioterapia , Adulto , Idoso , Transporte Biológico , Feminino , Meia-Vida , Humanos , Masculino , Pessoa de Meia-Idade , Radiometria , Risco , Adulto JovemRESUMO
This article reviews recent advances and applications of radionuclide therapy. Individualized precision medicine, new treatments, and the evolving role of radionuclide therapy are discussed.
Assuntos
Imagem Molecular , Terapia de Alvo Molecular , Imagem Multimodal , Neoplasias/diagnóstico por imagem , Neoplasias/radioterapia , Medicina de Precisão , 3-Iodobenzilguanidina/uso terapêutico , Humanos , Radioisótopos do Iodo/uso terapêutico , Microesferas , Radioisótopos/uso terapêutico , Compostos Radiofarmacêuticos/uso terapêutico , Dosagem Radioterapêutica , Iodeto de Sódio/uso terapêutico , Radioisótopos de Ítrio/uso terapêuticoRESUMO
PURPOSE: To investigate the possible differences between SPECT/CT based whole-remnant and maximum-voxel dosimetry in patients receiving radio-iodine ablation treatment of differentiated thyroid cancer (DTC). METHODS: Eighteen DTC patients were administered 1.11 GBq of 131I-NaI after near-total thyroidectomy and rhTSH stimulation. Two patients had two remnants, so in total dosimetry was performed for 20 sites. Three SPECT/CT scans were performed for each patient at 1, 2, and 3-7 days after administration. The activity, the remnant mass, and the maximum-voxel activity were determined from these images and from a recovery-coefficient curve derived from experimental phantom measurements. The cumulated activity was estimated using trapezoidal-exponential integration. Finally, the absorbed dose was calculated using S-values for unit-density spheres in whole-remnant dosimetry and S-values for voxels in maximum-voxel dosimetry. RESULTS: The mean absorbed dose obtained from whole-remnant dosimetry was 40 Gy (range 2-176 Gy) and from maximum-voxel dosimetry 34 Gy (range 2-145 Gy). For any given patient, the activity concentrations for each of the three time-points were approximately the same for the two methods. The effective half-lives varied (R = 0.865), mainly due to discrepancies in estimation of the longer effective half-lives. On average, absorbed doses obtained from whole-remnant dosimetry were 1.2 ± 0.2 (1 SD) higher than for maximum-voxel dosimetry, mainly due to differences in the S-values. The method-related differences were however small in comparison to the wide range of absorbed doses obtained in patients. CONCLUSIONS: Simple and consistent procedures for SPECT/CT based whole-volume and maximum-voxel dosimetry have been described, both based on experimentally determined recovery coefficients. Generally the results from the two approaches are consistent, although there is a small, systematic difference in the absorbed dose due to differences in the S-values, and some variability due to differences in the estimated effective half-lives, especially when the effective half-life is long. Irrespective of the method used, the patient absorbed doses obtained span over two orders of magnitude.
Assuntos
Radioisótopos do Iodo/uso terapêutico , Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único , Iodeto de Sódio/uso terapêutico , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Neoplasias da Glândula Tireoide/radioterapia , Transporte Biológico , Feminino , Humanos , Masculino , Imagens de Fantasmas , Controle de Qualidade , Radiometria , Iodeto de Sódio/metabolismo , Neoplasias da Glândula Tireoide/patologiaRESUMO
OBJECTIVE: Radioiodine, in low doses, has been used as a treatment modality for hyperthyroidism worldwide for a long time. However, there is little information available on the severity of cytotoxicity of radioiodine at these low doses. The present investigation aimed to study the cytogenetic toxicity of low-dose radioiodine in hyperthyroid patients using a cytokinesis-blocked micronuclei (MN) assay. MATERIALS AND METHODOLOGY: All of the patients received radioiodine in the form of sodium iodine (oral form). Blood samples of these patients were collected before therapy and 3 months after therapy, and lymphocytes were analysed for MN assay. RESULTS: Peripheral blood lymphocytes were analysed in 74 hyperthyroid patients (52 men, 22 women). The results indicated a positive relationship between age and the frequency of MN. However, there was no statistically significant difference in MN frequency at 3 months after therapy in comparison with that before therapy. CONCLUSION: This study showed that the cytogenetic damage produced by low-dose radioiodine was transient and reversible. Thus, patients can be motivated to undergo this safe and easy procedure as a modality of treatment for hyperthyroidism.
Assuntos
Hipertireoidismo/genética , Hipertireoidismo/radioterapia , Radioisótopos do Iodo/efeitos adversos , Radioisótopos do Iodo/uso terapêutico , Linfócitos/efeitos da radiação , Micronúcleos com Defeito Cromossômico/efeitos da radiação , Adolescente , Adulto , Idoso , Relação Dose-Resposta à Radiação , Feminino , Humanos , Masculino , Testes para Micronúcleos/métodos , Pessoa de Meia-Idade , Compostos Radiofarmacêuticos/efeitos adversos , Compostos Radiofarmacêuticos/uso terapêutico , Dosagem Radioterapêutica , Iodeto de Sódio/efeitos adversos , Iodeto de Sódio/uso terapêutico , Resultado do Tratamento , Adulto JovemAssuntos
Carcinoma Papilar, Variante Folicular/diagnóstico por imagem , Carcinoma Papilar, Variante Folicular/secundário , Carcinoma Papilar/diagnóstico por imagem , Carcinoma Papilar/secundário , Radioisótopos do Iodo/uso terapêutico , Doenças Renais Policísticas/diagnóstico por imagem , Compostos Radiofarmacêuticos/uso terapêutico , Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único , Iodeto de Sódio/uso terapêutico , Neoplasias da Glândula Tireoide/patologia , Imagem Corporal Total , Idoso de 80 Anos ou mais , Carcinoma Papilar/radioterapia , Carcinoma Papilar/cirurgia , Carcinoma Papilar, Variante Folicular/radioterapia , Carcinoma Papilar, Variante Folicular/cirurgia , Diagnóstico Diferencial , Reações Falso-Positivas , Feminino , Humanos , Radioisótopos do Iodo/farmacocinética , Neoplasias Primárias Múltiplas/cirurgia , Compostos Radiofarmacêuticos/farmacocinética , Radioterapia Adjuvante , Iodeto de Sódio/farmacocinética , Hormônios Tireóideos/uso terapêutico , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia , Distribuição Tecidual , UltrassonografiaAssuntos
Medicina Baseada em Evidências , Radioisótopos do Iodo/efeitos adversos , Compostos Radiofarmacêuticos/efeitos adversos , Iodeto de Sódio/efeitos adversos , Doenças da Glândula Tireoide/radioterapia , Glândula Tireoide/efeitos da radiação , Centers for Disease Control and Prevention, U.S. , Relação Dose-Resposta à Radiação , Interações Medicamentosas , Medicina Baseada em Evidências/métodos , Interações Alimento-Droga , Humanos , Radioisótopos do Iodo/administração & dosagem , Radioisótopos do Iodo/farmacocinética , Radioisótopos do Iodo/uso terapêutico , Cintilografia , Compostos Radiofarmacêuticos/administração & dosagem , Compostos Radiofarmacêuticos/farmacocinética , Compostos Radiofarmacêuticos/uso terapêutico , Iodeto de Sódio/administração & dosagem , Iodeto de Sódio/farmacocinética , Iodeto de Sódio/uso terapêutico , Doenças da Glândula Tireoide/diagnóstico por imagem , Doenças da Glândula Tireoide/metabolismo , Doenças da Glândula Tireoide/fisiopatologia , Glândula Tireoide/diagnóstico por imagem , Glândula Tireoide/metabolismo , Glândula Tireoide/fisiopatologia , Tireotropina/sangue , Distribuição Tecidual , Toxicologia/métodos , Estados UnidosRESUMO
Initial radiation exposure levels X (0) at 1 m from the navel of thyroid cancer patients were measured for 165 individuals at the time of ingestion. Some 61 patients had previously signed informed consent so only those patients could be assayed with regard to body parameters. While the activity was in the stomach, resultant X (0) values were seen to be linearly correlated with the total (131)I activity (A) given orally. Yet large differences in X (0) were seen; e.g., at A = 7.4 GBq, variations of a factor of four were found between the largest and smallest exposure rates. Correlation analyses were performed between normalized rate X (0)A-1 and several patient physical parameters. These included age, sex, height, weight, and BMI (body mass index). Only weight and BMI had significant linear correlation (p < 0.05) with normalized exposure rate. In the former case, the correlation coefficient ρ (weight) was -0.296 (p = 0.02). Using BMI as the independent variable, ρ (BMI) was -0.386 (p = 0.0021). With further analysis of the BMI variation, 95% confidence intervals could be determined at various BMI levels. For example, at 28 kg m(-2), the normalized rate varied between 0.039 and 0.0446 µGy h(-1) MBq(-1)-approximately a ±6.5% variation on the mean value of 0.0419 µGy h(-1) MBq(-1) at this BMI. Given such clinical information, differences in normalized exposure rate can be reduced to values on the order of ±10% or less for BMI values over the clinically relevant interval 20 to 40 kg m(-2).
Assuntos
Exposição Ambiental/análise , Iodeto de Sódio/uso terapêutico , Neoplasias da Glândula Tireoide/radioterapia , Índice de Massa Corporal , Ingestão de Alimentos , Família , Feminino , Humanos , Radioisótopos do Iodo/efeitos adversos , Masculino , Exposição Ocupacional/análise , Radiometria , Iodeto de Sódio/efeitos adversos , Neoplasias da Glândula Tireoide/fisiopatologiaRESUMO
This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 µg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.
Assuntos
Desenvolvimento Infantil , Suplementos Nutricionais , Lactente Extremamente Prematuro , Sistema Nervoso/efeitos dos fármacos , Nutrição Parenteral , Projetos de Pesquisa , Iodeto de Sódio/uso terapêutico , Fatores Etários , Protocolos Clínicos , Suplementos Nutricionais/efeitos adversos , Idade Gestacional , Humanos , Fenômenos Fisiológicos da Nutrição do Lactente , Recém-Nascido , Sistema Nervoso/crescimento & desenvolvimento , Estado Nutricional , Recomendações Nutricionais , Iodeto de Sódio/efeitos adversos , Fatores de Tempo , Resultado do TratamentoAssuntos
Medicina Baseada em Evidências , Radioisótopos do Iodo/uso terapêutico , Isótopos de Ferro/uso terapêutico , Iodeto de Sódio/uso terapêutico , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/secundário , Humanos , Metástase Linfática , Compostos Radiofarmacêuticos/uso terapêutico , Aço , Resultado do TratamentoRESUMO
PURPOSE: To evaluate two treatment modalities of dry socket in rats and to discuss the first findings of the molecular analysis in this experimental model. METHODS: 84 rats underwent a tooth extraction were divided in 4 groups: I-uninfected socket (control), II-infected socket without any treatment, III-infected socket treated with irrigation of 2 percent sodium iodide and 3 percent hydrogen peroxide solution, IV-infected socket submitted to curettage, irrigation with physiological saline solution and fulfilled with metronidazole paste as base. The groups were subdivided in postoperative sacrifice periods: 6/15/28 days. A quantitative and a qualitative microscopic analysis was performed. Also, a quantitative analysis was performed using a RealTimePCR to evaluate the genes expression in the wound healing: Collagen Type I/COL-I, vascular endothelial growth factor/VEGF, osteocalcin/OCN, alkaline phosphatase/ALP, runt-related transcription factor 2/RUNX2 and tumor necrosis factor alpha/TNF-α. RESULTS: The group I showed higher bone formation, followed by groups IV, III, II respectively. The group II presented higher inflammatory infiltrate and the wound healing was delayed compared with other groups. It was obtained a significant positive correlation between bone neoformation and the expression of OCN and RUNX2, inflammatory infiltrate with TNF-α and a negative correlation between bone neoformation and TNF-α. CONCLUSION: No significant difference was found between the treatments.
OBJETIVO: Avaliar duas modalidades de tratamento da alveolite em ratos e discutir os primeiros achados de uma análise molecular neste modelo experimental. MÉTODOS: 84 ratos foram submetidos a uma extração dentária e foram divididos em quatro grupos: I- alvéolo não infectado (controle), II- alvéolo infectado sem tratamento, III- alvéolo infectado tratado com irrigação de iodeto de sódio a 2 por cento e solução de peróxido de hidrogênio a 3 por cento, IV- alvéolo infectado submetido à curetagem, irrigação com solução salina fisiológica e preenchimento com pasta a base de metronidazol. Os grupos foram subdivididos em períodos de sacrifício pós-operatório: 6/15/28 dias. Uma análise quantitativa e qualitativa microscópica foi realizada. Além disso, uma análise quantitativa foi realizada utilizando RealTimePCR para avaliar a expressão de genes no reparo alveolar: o colágeno tipo I / COL-I, o fator de crescimento endotelial vascular / VEGF, osteocalcina / OCN, fosfatase alcalina / ALP, fator de transcrição runt relacionados 2 / RUNX2 e fator de necrose tumoral alfa / TNF-α. RESULTADOS: O grupo I mostrou maior formação óssea, seguido pelos grupos IV, III, II, respectivamente. O grupo II apresentou maior infiltrado inflamatório e a cicatrização foi atrasada em comparação com outros grupos. Foi obtida uma correlação positiva entre a neoformação óssea e a expressão de OCN e RUNX2, infiltrado inflamatório com TNF-α e uma correlação negativa entre a neoformação óssea e TNF-α. CONCLUSÃO: Nenhuma diferença significativa foi encontrada entre os tratamentos.
Assuntos
Animais , Masculino , Ratos , Anti-Infecciosos/uso terapêutico , Alvéolo Seco/tratamento farmacológico , Osteogênese/efeitos dos fármacos , Cicatrização/efeitos dos fármacos , Densidade Óssea , Alvéolo Seco/patologia , Peróxido de Hidrogênio/uso terapêutico , Metronidazol/uso terapêutico , Ratos Wistar , Reação em Cadeia da Polimerase em Tempo Real , Iodeto de Sódio/uso terapêutico , Fator de Necrose Tumoral alfa/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
PURPOSE: To evaluate two treatment modalities of dry socket in rats and to discuss the first findings of the molecular analysis in this experimental model. METHODS: 84 rats underwent a tooth extraction were divided in 4 groups: I-uninfected socket (control), II-infected socket without any treatment, III-infected socket treated with irrigation of 2% sodium iodide and 3% hydrogen peroxide solution, IV-infected socket submitted to curettage, irrigation with physiological saline solution and fulfilled with metronidazole paste as base. The groups were subdivided in postoperative sacrifice periods: 6/15/28 days. A quantitative and a qualitative microscopic analysis was performed. Also, a quantitative analysis was performed using a RealTimePCR to evaluate the genes expression in the wound healing: Collagen Type I/COL-I, vascular endothelial growth factor/VEGF, osteocalcin/OCN, alkaline phosphatase/ALP, runt-related transcription factor 2/RUNX2 and tumor necrosis factor alpha/TNF-α. RESULTS: The group I showed higher bone formation, followed by groups IV, III, II respectively. The group II presented higher inflammatory infiltrate and the wound healing was delayed compared with other groups. It was obtained a significant positive correlation between bone neoformation and the expression of OCN and RUNX2, inflammatory infiltrate with TNF-α and a negative correlation between bone neoformation and TNF-α. CONCLUSION: No significant difference was found between the treatments.
Assuntos
Anti-Infecciosos/uso terapêutico , Alvéolo Seco/tratamento farmacológico , Osteogênese/efeitos dos fármacos , Cicatrização/efeitos dos fármacos , Animais , Densidade Óssea , Alvéolo Seco/patologia , Peróxido de Hidrogênio/uso terapêutico , Masculino , Metronidazol/uso terapêutico , Ratos , Ratos Wistar , Reação em Cadeia da Polimerase em Tempo Real , Iodeto de Sódio/uso terapêutico , Fator de Necrose Tumoral alfa/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismoAssuntos
Adenocarcinoma Folicular/secundário , Catéteres , Erros de Diagnóstico , Radioisótopos do Iodo , Compostos Radiofarmacêuticos , Traqueostomia/instrumentação , Imagem Corporal Total , Adenocarcinoma Folicular/diagnóstico por imagem , Adenocarcinoma Folicular/radioterapia , Adenocarcinoma Folicular/cirurgia , Reações Falso-Positivas , Feminino , Seguimentos , Humanos , Radioisótopos do Iodo/farmacocinética , Radioisótopos do Iodo/uso terapêutico , Laringismo/cirurgia , Pessoa de Meia-Idade , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/cirurgia , Cintilografia , Compostos Radiofarmacêuticos/farmacocinética , Compostos Radiofarmacêuticos/uso terapêutico , Saliva/metabolismo , Iodeto de Sódio/uso terapêutico , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia , Tirotropina Alfa , Paralisia das Pregas Vocais/etiologia , Paralisia das Pregas Vocais/cirurgiaRESUMO
Candidiasis is a relevant problem in oral medicine practice. We compared the antimycotic activity of nystatin with a solution of sodium iodide associated to salicylic acid (SISA) in the topical management of chronic candidiasis. Consecutive patients affected by chronic candidiasis were randomly allocated to SISA (group A) or nystatin (group B). VAS and swab scores were recorded at the beginning and at the end of the study while the healing index was evaluated at the end of the study only. Data were analyzed by STATA 10 MP. Forty patients (20 male, 20 female) were randomized. SIAS was as effective as nystatin in affecting VAS (p greater than 0.05) and swab score (p greater than 0.05). A statistically significant reduction (p less than 0.05) of healing index was observed in both groups. No side effects were reported. SISA topical application, shows a comparable efficacy to the nystatin in the management of chronic oral candidiasis. Its use could represent an adequate alternative to the nystatin above all in the cases of drug-resistance. Further large scale randomized trials are warranted to confirm these preliminary findings.
Assuntos
Candidíase Bucal/tratamento farmacológico , Ácido Salicílico/uso terapêutico , Iodeto de Sódio/uso terapêutico , Adulto , Idoso , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nistatina/uso terapêutico , Medição da DorRESUMO
OBJECTIVES: The first objective of this study was to evaluate the radiological impact on relatives and the environment because of outpatient treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI. The second objective was to determine, analyze, and evaluate whole-body radiation dose to caregivers, the production of contaminated solid waste, and the potentiality of radiation dose and surface contamination existing inside patients' households. METHODS: Twenty patients were treated on an outpatient basis, taking into consideration their acceptable living conditions, interests, and willingness to comply with medical and radiation-safety guidelines. The caregivers themselves, as well as the potentiality of the radiation dose inside patients' residences, were monitored with a thermo-luminescence dosimeter. Surface contamination and contaminated solid wastes were identified and measured by using a Geiger-Müller detector. RESULTS AND DISCUSSION: Twenty-six monitored individuals received accumulated effective radiation doses of less than 1.0 mSv, and only one 2.8 mSv, throughout the 7 days of measurement. The maximum registered value for the potential of radiation dose inside all living areas was 1.30 mSv. The monitored surface contamination inside patients' dwellings showed a mean value of 4.2 Bq/cm for all surfaces found to be contaminated. A total of 2.5 l of contaminated solid waste was generated by the patients with 3.33 MBq of all estimated activity. CONCLUSION: This study revealed that the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, can be safe when overseen by qualified professionals and with an adapted radiation-protection guideline. Even considering the radioiodine activity level and the dosimetric methodology applied here, negligible human exposure and a nonmeasurable radiological impact to the human environment were found.
Assuntos
Assistência Ambulatorial , Doses de Radiação , Segurança , Iodeto de Sódio/química , Iodeto de Sódio/uso terapêutico , Neoplasias da Glândula Tireoide/radioterapia , Adulto , Assistência Ambulatorial/normas , Cuidadores , Família , Feminino , Habitação , Humanos , Radioisótopos do Iodo/química , Masculino , Pessoa de Meia-Idade , Proteção Radiológica , Dosagem Radioterapêutica , Fatores de Tempo , Irradiação Corporal TotalRESUMO
OBJETIVO: Avaliar a mudança no perfil e abordagem dos pacientes com doença de Graves submetidos a dose terapêutica de radioiodo. MATERIAIS E MÉTODOS: Avaliamos, retrospectivamente, 226 pacientesportadores de doença de Graves submetidos a dose terapêutica de radioiodo entre janeiro de 1990 e dezembro de 2001. O período de 12 anos foi dividido em três períodos de 4 anos para fins de análise estatística,sendo comparadas variáveis clínicas e laboratoriais nos períodos descritos. RESULTADOS: Constatamos que o número de pacientes encaminhados para a dose terapêutica, assim como o percentual de pacientes do sexo feminino (de 62% para 86%; p = 0,005), tiveram incremento significativo. Houve aumento significativo no percentual de pacientes em uso de metimazol previamente à dose terapêutica (de 9,1% para 35,6%;p = 0,03). A dose média de iodo administrada também teve incremento significativo (de 7,6 mCi para 12,7mCi; p = 0,000003), com reflexo direto em um maior percentual de pacientes curados (de 55,6% para 83,7%; p = 0,004) um ano pós-dose terapêutica. CONCLUSÃO: A dose terapêutica de radioiodo tem sido um método cada vez mais aceito nos pacientes com doença de Graves e a dose administrada tem sido cada vez maior, no intuito de cura permanente e diminuição das chances de recidiva.
OBJECTIVE: To evaluate the changes in clinical parameters and in the approach to patients submitted to radioiodine therapy for Graves' disease. MATERIALS AND METHODS: Dossiers of 226 patients submitted to radioiodine therapy for Graves' disease in the period between January 1990 and December 2001 were retrospectively evaluated. For the purposes of statistical analysis, the 12-year period was subdivided into three periods of 4 years, with a comparison of clinical and laboratory variables in these periods. RESULTS: The authors have observed that the total number of patients referred for radioiodine therapy as well as the percentage of female patients presented a significant increase (from 62% to 86%; p = 0.005). The percentage of patients pretreated with methimazole before radioiodine therapy increased significantly (from 9.1% to35.6%; p = 0.03). The mean radioiodine dose delivered has also presented a significant increase (from 7.6 mCi to 12.7 mCi; p = 0.000003) with a direct reflection on a higher percentage of patients cured one year after the radioiodine therapy (from 55.6% to 83.7%; p = 0.004). CONCLUSION: Radioiodine therapy has increasingly been accepted for treatment of patients with Graves' disease and the doses delivered have increased to achieve a permanent cure as well as a reduction of the chances of recurrence.
Assuntos
Humanos , Feminino , Doença de Graves , Iodeto de Sódio/administração & dosagem , Iodeto de Sódio/uso terapêutico , Doença de Graves/tratamento farmacológico , Hipertireoidismo , Radioisótopos do Iodo , Metimazol , Estudos RetrospectivosRESUMO
UNLABELLED: The aim of this study was to evaluate the influence of chlorhexidine gluconate, sodium fluoride and sodium iodine on mutans streptococci counts in saliva of irradiated patients. MATERIAL AND METHODS: Forty-five patients were separated into three experimental groups and received chlorhexidine (0.12%), sodium fluoride (0.5%) or sodium iodine (2%), which were used daily during radiotherapy and for 6 months after the conclusion of the treatment. In addition, a fourth group, composed by 15 additional oncologic patients, who did not receive the mouthwash or initial dental treatment, constituted the control group. Clinical evaluations were performed in the first visit to dental clinic, after initial dental treatment, immediately before radiotherapy, after radiotherapy and 30, 60, 90 days and 6 months after the conclusion of radiotherapy. After clinical examinations, samples of saliva were inoculated on SB20 selective agar and incubated under anaerobiosis, at 37ºC for 48 h. Total mutans streptococci counts were also evaluated by using real-time PCR, through TaqMan system, with specific primers and probes for S. mutans and S. sobrinus. RESULTS: All preventive protocols were able to reduce significantly mutans streptococci counts, but chlorhexidine gluconate was the most effective, and induced a significant amelioration of radiotherapy side effects, such as mucositis and candidosis. CONCLUSION: These results highlights the importance of the initial dental treatment for patients who will be subjected to radiotherapy for head and neck cancer treatment.
Assuntos
Cárie Dentária/prevenção & controle , Neoplasias de Cabeça e Pescoço/radioterapia , Higiene Bucal/normas , Streptococcus mutans/efeitos dos fármacos , Adulto , Anti-Infecciosos Locais/uso terapêutico , Cariostáticos/uso terapêutico , Clorexidina/análogos & derivados , Clorexidina/uso terapêutico , Contagem de Colônia Microbiana , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Radioterapia/efeitos adversos , Saliva/microbiologia , Fluoreto de Sódio/uso terapêutico , Iodeto de Sódio/uso terapêutico , Estatísticas não Paramétricas , Streptococcus mutans/isolamento & purificação , Fatores de Tempo , Adulto JovemRESUMO
The aim of this study was to evaluate the influence of chlorhexidine gluconate, sodium fluoride and sodium iodine on mutans streptococci counts in saliva of irradiated patients. MATERIAL AND METHODS: Forty-five patients were separated into three experimental groups and received chlorhexidine (0.12 percent), sodium fluoride (0.5 percent) or sodium iodine (2 percent), which were used daily during radiotherapy and for 6 months after the conclusion of the treatment. In addition, a fourth group, composed by 15 additional oncologic patients, who did not receive the mouthwash or initial dental treatment, constituted the control group. Clinical evaluations were performed in the first visit to dental clinic, after initial dental treatment, immediately before radiotherapy, after radiotherapy and 30, 60, 90 days and 6 months after the conclusion of radiotherapy. After clinical examinations, samples of saliva were inoculated on SB20 selective agar and incubated under anaerobiosis, at 37ºC for 48 h. Total mutans streptococci counts were also evaluated by using real-time PCR, through TaqMan system, with specific primers and probes for S. mutans and S. sobrinus. RESULTS: All preventive protocols were able to reduce significantly mutans streptococci counts, but chlorhexidine gluconate was the most effective, and induced a significant amelioration of radiotherapy side effects, such as mucositis and candidosis. CONCLUSION: These results highlights the importance of the initial dental treatment for patients who will be subjected to radiotherapy for head and neck cancer treatment.